Results 21 to 30 of about 65,815 (207)

The association of bullous pemphigoid with dipeptidyl-peptidase 4 inhibitors: a ten-year prospective observational study

open access: yesBMC Endocrine Disorders, 2021
Background Bullous pemphigoid is the most common bullous chronic autoimmune skin disease. Recent studies have suggested dipeptidyl-peptidase 4 inhibitors as possible predisposing agents of bullous pemphigoid.
Vaia Lambadiari   +10 more
doaj   +1 more source

Combined treatment with dipeptidyl peptidase 4 (DPP4) inhibitor sitagliptin and elemental diets reduced indomethacin-induced intestinal injury in rats via the increase of mucosal glucagon-like peptide-2 concentration. [PDF]

open access: yes, 2015
The gut incretin glucagon-like peptide-1 (GLP-1) and the intestinotropic hormone GLP-2 are released from enteroendocrine L cells in response to ingested nutrients.
Abe, Yosuke   +17 more
core   +1 more source

Effects of vildagliptin on ventricular function in patients with type 2 diabetes mellitus and heart failure: a randomized placebo-controlled trial [PDF]

open access: yes, 2017
Objectives: This study sought to examine the safety of the dipeptidyl peptidase-4 inhibitor, vildagliptin, in patients with heart failure and reduced ejection fraction.
Bolli, Geremia B.   +7 more
core   +2 more sources

Seprase: An overview of an important matrix serine protease [PDF]

open access: yes, 2008
Seprase or Fibroblast Activation Protein (FAP) is an integral membrane serine peptidase, which has been shown to have gelatinase activity. Seprase has a dual function in tumour progression.
Abbott   +115 more
core   +1 more source

Synthesis of new DPP-4 inhibitors based on a novel tricyclic scaffold [PDF]

open access: yes, 2015
A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogues of biologically active molecules will be discussed.
Biftu T.   +14 more
core   +3 more sources

Dipeptidyl peptidase-4 inhibitor-related renal disease

open access: yesJournal of Diabetes and its Complications, 2023
Dipeptidyl peptidase-4 (DPP-4) inhibitors are widely used to treat type 2 diabetes (T2D). Lowering blood glucose is expected also to reduce the progression of diabetic nephropathy. We experienced a patient with T2D who achieved good glycemic control with a DPP-4 inhibitor but experienced rapid deterioration of renal function.
Atsuhiko, Suenaga   +16 more
openaire   +2 more sources

The persistent inhibitory properties of saxagliptin on renal dipeptidyl peptidase-4: Studies with HK-2 cells in vitro and normal rats in vivo

open access: yesJournal of Pharmacological Sciences, 2017
Saxagliptin, a potent and selective DPP-4 inhibitor, exhibits a slow dissociation from DPP-4. We investigated the sustained effects of saxagliptin on renal DPP-4 activity in a washout study using renal tubular (HK-2) cells, and in a pharmacodynamic study
Masako Uchii   +7 more
doaj   +1 more source

What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]

open access: yes, 2019
Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra   +13 more
core   +1 more source

Extra virgin olive oil use is associated with improved post-prandial blood glucose and LDL cholesterol in healthy subjects [PDF]

open access: yes, 2015
Extra virgin olive oil (EVOO) is a key component of the Mediterranean diet and seems to account for the protective effect against cardiovascular disease.
ANGELICO, Francesco   +10 more
core   +1 more source

Dipeptidyl peptidase-4 levels are increased and partially related to body fat distribution in patients with familial partial lipodystrophy type 2

open access: yesDiabetology & Metabolic Syndrome, 2017
Background Dipeptidyl peptidase-4 (DDP4) is an enzyme responsible for glucagon-like peptide-1 inactivation and plays an important role in glucose metabolism.
Cynthia Melissa Valerio   +6 more
doaj   +1 more source

Home - About - Disclaimer - Privacy